Adjusted rate ratio of fatal and non-fatal acute myocardial infarction (MI) for nebulised and oral β2 agonist use during the year before the index date
| Adjusted* | |||||
|---|---|---|---|---|---|
| Cases (n=1127) | Controls (n=10766) | Crude rate ratio | Rate ratio | 95% CI | |
| *Adjusted for sex, number of prescriptions for oral corticosteroids, nasal corticosteroids, inhaled corticosteroids, inhaled β2 agonist, oral β2 agonist and xanthines in the year before the index date, and presence of cardiovascular risk factors (angina, hypertension, congestive heart failure, arrhythmia, hyperlipidaemia and diabetes) in the year before the index date. | |||||
| †Rate ratio per additional 10 prescriptions. | |||||
| ‡Adjusted for sex, number of prescriptions for oral corticosteroids, nasal corticosteroids, inhaled corticosteroids, inhaled β2 agonist, nebulised β2 agonist and xanthines in the year before the index date, and presence of cardiovascular risk factors (angina, hypertension, congestive heart failure, arrhythmia, hyperlipidaemia, and diabetes) in the year before the index date. | |||||
| Nebulised β2 agonist use* during year before index date: | |||||
| No use | 87.2 | 90.7 | 1.00 | 1.00 | Reference |
| Any use | 12.8 | 9.3 | 1.44 | 1.12 | 0.90 to 1.38 |
| No of prescriptions† | 0.7 (2.5) | 0.6 (2.4) | 1.20 | 0.91 | 0.69 to 1.19 |
| Oral β2 agonist use‡ during year before index date | |||||
| No use | 89.1 | 89.7 | 1.00 | 1.00 | Reference |
| Any use | 10.9 | 10.3 | 1.05 | 0.99 | 0.80 to 1.23 |
| No of prescriptions† | 0.5 (1.8) | 0.5 (1.9) | 0.92 | 0.79 | 0.55 to 1.12 |